Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening

International Journal of Cancer

Volumn 123, Issue 12, 2008, Pages 2902-2906

  Kotaniemi Talonen, Laura ^a   Malila, Nea ^a   Nieminen, Pekka ^b   Anttila, Ahti ^a   Tarkkanen, Jussi ^b   Laurila, Pekka ^b   Hakama, Matti ^c  

^a FINNISH CANCER REGISTRY   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Cervical cancer; HPV DNA testing; Hybrid Capture 2; rlu ratio; Routine screening

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CANCER SCREENING; COLPOSCOPY; CONTROLLED STUDY; CYTOLOGY; FEMALE; FINLAND; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; WART VIRUS;

ADULT; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 57349159443     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23839     Document Type: Article

References (23)

1. Koss LG. The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA 1989;261:737-43.
2. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-19.
3. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of metaanalyses. Vaccine 2006;24(Suppl 3):S78-89.
4. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and metaanalysis of non-randomized studies. Gynecol Oncol 2007;104:232-46.
5. The Working group of IARC. IARC handbooks of cancer prevention: cervical cancer, vol. 10. Lyon: IARC Press, 2005.
6. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 2005;93:862-7.
7. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-101.
8. Anttila A, Hakama M, Kotaniemi-Talonen L, Nieminen P. Alternative technologies in cervical cancer screening: a randomised evaluation trial. BMC Public Health 2006;6:252.
9. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985;4:213-26.
10. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C, Pierotti P, Rizzolo R, Segnan N, Schincaglia P, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006;7:547-55.
11. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006;98:765-74.
12. Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000;92:818-25.
13. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, Alfaro M, Hutchinson M, Morales J, Greenberg MD, Lorincz AT. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000; 283:87-93.
14. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;84:1616-23.
15. Kulmala SM, Syrjanen S, Shabalova I, Petrovichev N, Kozachenko V, Podistov J, Ivanchenko O, Zakharenko S, Nerovjna R, Kljukina L, Branovskaja M, Grunberga V, et al. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. J Clin Microbiol 2004;42:2470-5.
16. Szarewski A, Cadman L, Mallett S, Austin J, Londesborough P, Waller J, Wardle J, Altman DG, Cuzick J. Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting. J Med Screen 2007;14:34-42.
17. Mayrand MH, Duarte-Franco E, Coutlee F, Rodrigues I, Walter SD, Ratnam S, Franco EL. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006;119:615-23.
18. Viikki M, Pukkala E, Hakama M. Risk of cervical cancer after a negative Pap smear. J Med Screen 1999;6:103-7.
19. Anttila A, Pukkala E, Soderman B, Kallio M, Nieminen P, Hakama M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer 1999;83:59-65.
20. Leinonen M, Kotaniemi-Talonen L, Anttila A, Dyba T, Tarkkanen J, Nieminen P. Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland. Int J Cancer 2008;123:1344-9.
21. Castle PE, Lorincz AT, Mielzynska-Lohnas I, Scott DR, Glass AG, Sherman ME, Schussler JE, Schiffman M. Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible. J Clin Microbiol 2002;40:1088-90.
22. Hakama M. Trends in the incidence of cervical cancer in the Nordic countries. In: Magnus K, ed. Trends in cancer incidence. Washington: Hemisphere Publishing Corporation, 1982. 279-92.
23. Kotaniemi-Talonen L, Anttila A, Malila N, Tarkkanen J, Laurila P, Hakama M, Nieminen P. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer 2008;44:565-71.